Regeneron is interested in obesity treatments that combat muscle loss
Regeneron is interested in obesity treatments that combat muscle loss — potentially adding trevogrumab or garetosmab to semaglutide in a bid to improve the way a patient loses weight.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today, we talk about two players that want to join the obesity market with updates to the GLP-1 class: Amgen and Regeneron. Also, a draft bill in Congress would restrict U.S. involvement with Chinese biotechs.
What's Your Reaction?
